Need for immunization against influenza. Need for immunization against influenza
Conditions
Interventions
Intervention 1: The first group (Intervention): 250mg Imiquimod 5% cream (Aldara)
was rubbed on deltoid region of right arm, and after 15 minutes, 0.25cc of trivalent influenza vaccine was injected in
Treatment - Drugs
Placebo
Prevention
The first group (Intervention): 250mg Imiquimod 5% cream (Aldara)
was rubbed on deltoid region of right arm, and after 15 minutes, 0.25cc of trivalent influenza vaccine was injected intradermal.
The second group (Intervention/Control): received 0.25cc trivalent influenza vaccine via intradermal route after rubbing 250 mg aqueous cream in the same region with the
same prior interval.
The a
The third group (control): 0.5 cc trivalent influenza vaccine was injected intramuscular after using 250 mg aqueous topical cream on the same area.
The applied inactivated trivalent influenza
Sponsors
Vice chancellor for research, Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Individuals more than 18 years old who are known to have end stage renal disease and need routine dialysis (i.e. at least 2 times a week for more than one month). Exclusion criteria: History of influenza or other viral diseases and also live viral vaccination in recent 4 weeks; History of influenza vaccination in prior 6 months; Prior history of hypersensitivity to egg, components of influenza vaccine; Documented primary or secondary immunosuppression especially impaired cellular and humoral immunity.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparing the immunogenicity against influenza vaccine via intradermal and intramuscular routes. Timepoint: Obtaining blood samples for antibody titration, before and 14 to 21 days after vaccination. Method of measurement: Antibody titration within the sera obtained before and after vaccination, by hemagglutination inhibition assay test. | — |
Secondary
| Measure | Time frame |
|---|---|
| The effect of imiquimod pretreatment before intradermal influenza vaccination on immunogenicity of vaccine. Timepoint: Antibody titration within blood samples obtained before and 14 to 21 days after vaccination. Method of measurement: Antibody titration within the sera obtained before and after vaccination, by hemagglutination inhibition assay test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Doosti
Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sci
Outcome results
None listed